InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,444.00
(
2.16%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
-1.03%
)
Bitcoin
62,881.62
(
6.36%
)
Post# of 251701
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119564
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 164769

Wednesday, 07/31/2013 4:26:47 PM

Wednesday, July 31, 2013 4:26:47 PM

Post# of 251701
ENTA is a screaming buy based on valuation, IMO. ABT-450 is a so-so drug, but the economics of ENTA’s partnership with ABBV (#msg-89280314) almost assure that the share price will rise unless a safety problem derails ABBV’s HCV program (#msg-90408583, #msg-90352754). On top of that, you get the NVS partnership for free.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up